[1]李 尤,王子卫.食管胃结合部腺癌的研究进展[J].医学信息,2019,32(13):39-45.[doi:10.3969/j.issn.1006-1959.2019.13.013]
　LI You,WANG Zi-wei.Advances in Research on Esophageal and Gastric Junction Adenocarcinoma[J].Journal of Medical Information,2019,32(13):39-45.[doi:10.3969/j.issn.1006-1959.2019.13.013]
点击复制

食管胃结合部腺癌的研究进展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年13期
页码:
39-45
栏目:
综述
出版日期:
2019-07-01

文章信息/Info

Title:
Advances in Research on Esophageal and Gastric Junction Adenocarcinoma
文章编号:
1006-1959（2019）13-0039-07
作者:
李 尤; 王子卫
重庆医科大学附属第一医院胃肠外科，重庆 400016
Author(s):
LI You; WANG Zi-wei
Department of Gastroenterology,the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016,China
关键词:
食管胃结合部腺癌; 分型; 分期; 争议; 外科手术
Keywords:
Key words：Esophagogastric junction adenocarcinoma; Typing; Staging; Controversy; Surgery
分类号:
R735
DOI:
10.3969/j.issn.1006-1959.2019.13.013
文献标志码:
A
摘要:
食管胃结合部腺癌（AEG）是近年来发病率迅速上升的一种恶性肿瘤，预后较差，生存结局不良。由于其特殊的解剖部位和独特的生物学行为，目前人们对AEG的界定、病因、分型、分期、诊断、治疗等各方面认识仍处于探索及过渡阶段。国内外对该疾病的诊疗指南规范经过20多年的发展，依然存在许多争议话题。本文总结归纳了AEG的相关问题，并对其及研究热点进行综述，旨在为临床工作及试验提供有益的启示。
Abstract:
Abstract：Esophageal and gastric junctional adenocarcinoma (AEG) is a malignant tumor with a rapid increase in incidence in recent years. The prognosis is poor and the survival outcome is poor. Due to its special anatomical location and unique biological behavior, people's understanding of AEG's definition, etiology, classification, staging, diagnosis, treatment and other aspects are still in the exploration and transition stage. After more than 20 years of development, the guidelines for the diagnosis and treatment of this disease at home and abroad, there are still many controversial topics. This paper summarizes the related issues of AEG, and summarizes its research hotspots, and strives to provide useful inspiration for clinical work and experiments.

参考文献/References:

[1]Buas MF,Vaughan TL.Epidemiology and risk factors for gastroesophageal junction tumors:Understanding the rising incidence of this disease[J].Seminarsin Radiation Oncology,2013,23(1):3-9. [2]Shinichi Hasegawa,Takaki Yoshikawa,Toru Aoyama,et al.Esophagus or Stomach?The Seventh TNM Classification for Siewert TypeII/III Junctional Adenocarcinoma[J].Annals of Surgery Oncology,2013,20(3):773-779. [3]Siewert JR,Feith M,Werner M,et al.Adenocarcinoma of the esophagogastric junction:results of surgical therapy based on anatomical/topographic classification in 1002 consecutive patients-Discussion[J].Annals of Surgery,2000,232(3):353-361. [4]Zhang XD,Shu YQ,Liang J,et al.Combination chemotherapy with paclitaxel,cisplatin and fluorouracil for patients with advanced and metastatic gastric or esophagogastric junction adenocarcinoma:a multicenter prospective study[J].Chinese Journal of Cancer Research,2012,24(4):291-298. [5]Pedrazzani C.Should Adenocarcinoma of the Esophagogastric Junction Be Classified as Gastric or Esophageal Cancer,or Else as a Distinct Clinical Entity?[J].Annals of Surgery,2015,261(4):e107. [6]国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟,中国医师协会内镜医师分会腹腔镜外科专业委员会,中国医师协会外科医师分会上消化道外科医师专业委员会,等.食管胃结合部腺癌外科治疗中国专家共识(2018年版)[J].中华胃肠外科杂志,2018,21(9):961-975. [7]Suh YS,Han DS,Kong SH,et al.Should Adenocarcinoma of the Esophagogastric Junction Be Classified as Esophageal Cancer A Comparative Analysis According to the Seventh AJCC TNM Classification[J].Annals of Surgery,2012,255(5):908-915. [8]Siewert JR.Carcinoma of the cardia:carcinoma of the gastroesophageal junction-classification,pathology and extent of resection[J].Dis Eso,1996,9(3):173-182. [9]Siewert JR,Stein HJ.Classification of adenocarcinoma of the oesophagogastric junction[J].Br J Surg,1998,85(11):1457-1459. [10]Hosokawa Y,Kinoshita T,Konishi M,et al.Clinicopathological Features and Prognostic Factors of Adenocarcinoma of the Esophagogastric Junction According to Siewert Classification:Experiences at a Single Institution in Japan[J].Annals of Surgical Oncology,2012,19(2):677-683. [11]Dresner SM,Lamb PJ,Bennett MK,et al.The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction[J].Surgery,2001,129(1):103-109. [12]Sobin LH,Gospodarowicz MK,Wittekind C.(eds).Oesophagus including oesophagogastric junction,TNM Classification of Malignant Tumours[M].7th edn.New York:Wiley-Blackwell,2009:66-72. [13]Kusano C,Gotoda T,Khor CJ,et al.Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan[J].Journal of Gastroenterology and Hepatology,2008,23(11):1662-1665. [14]Xiao WG,Ma K,Peng L,et al.Characteristics of lymphatic metastasis and surgical approach of adenocarcinoma of the esophagogastric junction[J].Chinese Journal of Gastrointestinal Surgery,2012,15(9):897-900. [15]Yang H,Wu AW,Ji JF.Adenocarcinoma of the esophagogastric junction according to Siewert classification:a clinical study of 471 cases[J].Chinese Journal of Practical Surgery,2012,32(4): 310-315. [16]Felley C,Bouzourene H,Marianne Bründler,et al.Age,smoking and overweight contribute to the development of intestinal metaplasia of the cardia[J].World Journal of Gastroenterology,2012,18(17):2076-2083. [17]Vicari JJ,Peek RM,Falk GW,et al.The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease[J].Gastroenterology,1998,115(1):50-57. [18]Rathod KJ,Kalayarasan R,Kate V,et al.Helicobacter pylori positivity in esophageal and esophagogastric junction adenocarcinoma[J].Indian Journal of Gastroenterology Official Journal of the Indian Society of Gastroenterology,2008,27(6):248. [19]Hasegawa S,Yoshikawa T.Adenocarcinoma of the esophagogastric junction:incidence,characteristics,and treatment strategies[J].Gastric Cancer,2010,13(2):63-73. [20]Fang WL,Wu CW,Chen JH,et al.Esophagogastric Junction Adenocarcinoma According to Siewert Classification in Taiwan[J].Annals of Surgical Oncology,2009,16(12):3237-3244. [21]Rice TW,Blackstone EH,Rusch VW.7th Edition of the AJCCCancer StagingManual:Esophagus and Esophagogastric Junction[J].Annals of Surgical Oncology,2010,17(7):1721-1724. [22]Kawaguchi T,Komatsu S,Ichikawa D,et al.Comparison of Prognostic Compatibility between Seventh AJCC/TNM of the Esophagus and 14th JCGC Staging Systems in Siewert Type Ⅱ Adenocarcinoma[J].Anticancer Research,2013,33(8):3461-3465. [23]Huang Q,Shi J,Feng A,et al.Gastric cardiac carcinomas involving the esophagus are more adequately staged as gastric cancers by the 7th edition of the American Joint Commission on Cancer Staging System[J].Modern Pathology,2011,24(1):138-146. [24]Gertler R,Stein HJ,Loos M,et al.How to Classify Adenocarcinomas of the Esophagogastric Junction: As Esophageal or Gastric Cancer?[J].The American Journal of Surgical Pathology,2011,35(10):1512-1522. [25]Amin MB,Edge S,Greene FL,et al.AJCC cancer stagingmanual[M].8th ed.New York: Springer,2017:185-202. [26]陕飞,李子禹,张连海,等.国际抗癌联盟及美国肿瘤联合会胃癌TNM分期系统(第8版)简介及解读[J].中国实用外科杂志,2017(1):20-22. [27]Chen XF,Zhang B,Chen ZX,et al.Gastric Tube Reconstruction Reduces Postoperative Gastroesophageal Reflux in Adenocarcinoma of Esophagogastric Junction[J].Digestive Diseases & Sciences,2012,57(3):738-745. [28]Goto H,Tokunaga M,Miki Y,et al.The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type Ⅱ and Siewert typeⅢ patients[J].Gastric Cancer,2015,18(2):375-381. [29]Liu Y,Han G,Wang G,et al.Proximal gastrectomy versus total gastrectomy foradenocarcinoma of esophagogastric junction:a meta-analysis[J].Chinese Journal of Gastrointestinal Surgery,2014,17(4):373. [30]Takiguchi N,Takahashi M,Ikeda M,et al.Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by Postgastrectomy Syndrome Assessment Scale (PGSAS-45):a nationwide multi-institutional study[J].Gastric Cancer,2015,18(2):407-416. [31]Ito H,Clancy TE,Osteen RT,et al.Adenocarcinoma of the gastric cardia: What is the optimal surgical approach?[J].Journal of the American College of Surgeons,2004,199(6):880-886. [32]Barbour AP,Rizk NP,Gonen M,et al.Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome[J].Annals of Surgery,2007,246(1):1. [33]Mine S,Sano T,Hiki N,et al.Proximal margin length with transhiatal gastrectomy for Siewert type II and III adenocarcinomas of the oesophagogastric junction[J].British Journal of Surgery,2013,100(8):1050-1054. [34]Ter-Ovanesov M,Yalcin S,Zalcberg J,et al.Registry of gastric cancer treatment evaluation (REGATE): I baseline disease characteristics[J].Asia-Pacific Journal of Clinical Oncology,2014,10(1):38-52. [35]Hulscher J.Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus[J].N Engl J Med,2002,347(21):1662-1669. [36]Sasako M,Sano T,Sairenji M,et al.Left thoraco-abdominal approach (LT) compared with abdominal and transhiatal approach (AT) for cardia or sub-cardia cancer.Results of a surgical randomized controlled trial (JCOG9502)[J].Journal of Clinical Oncology,2004,22(14_suppl):4000. [37]Mitsuru Sasako,Takeshi Sano,Seiichiro Yamamoto,et al.Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial[J].The Lancet,Oncology,2006,7(8):644-651. [38]Yoon SS,Yang HK.Lymphadenectomy for Gastric Adenocarcinoma:Should West Meet East?[J].The Oncologist,2009,14(9):871-882. [39]Edge SB,Compton CC.The American Joint Committee on Cancer:the 7th Edition of the AJCC Cancer Staging Manualand the Future of TNM[J].Annals of Surgical Oncology,2010,17(6):1471-1474. [40]Saha S,Dehn TCB.Ratio of invaded to removed lymph nodes as a prognostic factor in adenocarcinoma of the distal esophagus and esophagogastric junction[J].Diseases of the Esophagus,2001,14(1):32-36. [41]Wayman J,Bennett MK,Raimes SA,et al.The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction[J].British Journalof Cancer,2002,86(8):1223-1229. [42]李守淼,李子禹,季鑫.SiewertⅡ型胃食管结合部腺癌淋巴结转移的特点[J].中华肿瘤杂志,2013,35(4):288-291. [43]蔡杰,彭俊,王文凭,等.SiewertⅡ型食管胃结合部腺癌淋巴结转移规律及手术方式的选择[J].中国胸心血管外科临床杂志,2016,23(2):151-155. [44]Zhang XY,Ping H,Yang JY,et al.Comparison of the efficacies of laparoscopic-assisted and open total gastrectomy for the treatment of Siewert Ⅱ and Ⅲ adenocarcinoma of the esophagogastric junction[J].Chinese Journal of Clinicians,2016,10(15):2219-2222. [45]Zhang X,Pei Q,Li T,et al.System analysis of curative effect on adenoearcinoma gastric of esophago-junction between laparoscopic and open operation[J].Journal of Lanzhou University(Medical Sciences),2015,41(1):63-67. [46]Wang G,Wu A,Cheng X,et al.Risk factors associated with early recurrence of adenocarcinoma of gastroesophageal junction after curative resection[J].Chinese Journal of Cancer Research,2013,25(3):334-338.

相似文献/References:

[1]陆佳陵,高仕长.胫骨平台骨折的诊疗进展[J].医学信息,2019,32(07):53.[doi:10.3969/j.issn.1006-1959.2019.07.017]
　LU Jia-ling,GAO Shi-chang.Reseatch on the Diagnosis and Treatment of Tibial Plateau Fractures[J].Journal of Medical Information,2019,32(13):53.[doi:10.3969/j.issn.1006-1959.2019.07.017]
[2]王洪志,杨 林,熊 波,等.不同分型腺性膀胱炎中CK20、Ki67、Ras P21蛋白表达及 临床意义研究[J].医学信息,2019,32(13):94.[doi:10.3969/j.issn.1006-1959.2019.13.026]
　WANG Hong-zhi,YANG Lin,XIONG Bo,et al.Expression of CK20,Ki67 and Ras P21 Proteins in Different Types of Glandular Cystitis and Clinical Significance[J].Journal of Medical Information,2019,32(13):94.[doi:10.3969/j.issn.1006-1959.2019.13.026]

更新日期/Last Update: 2019-07-01